| 摘要 |
The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 75% of said botulinum toxin type B is activated (i.e., "nicked"), and wherein at least 75% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., "stripped"). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 75% of said botulinum toxin type B is nicked, and wherein at least 75% of said nicked botulinum toxin type B is stripped. The invention also relates to a process of stripping botulinum toxin type B, comprising the stages of: cell growth, activation, purification, and dilution; wherein at least one dissociating reagent is administered to a volume of said botulinum toxin type B; and wherein said dissociating reagent administered increases the levels of stripped botulinum toxin type B to at least 75%.
|
